Shopping Cart
- Remove All
Your shopping cart is currently empty
Lanadelumab
🥰Excellent
Catalog No. T76710Cas No. 1426055-14-2
Alias SHP-643, SHP643, DX-2930, DX2930
Lanadelumab (SHP643) is a humanized IgG1 monoclonal antibody targeting plasma kallikrein (pKal) with a Ki value of 0.12 nM. Lanadelumab effectively inhibits both free pKal and its interaction with high molecular weight kininogen (HMWK)-bound pKal. Lanadelumab has demonstrated potential in hereditary angioedema research and represents a promising therapeutic antibody for studying kallikrein-kinin system regulation.
Lanadelumab
Lanadelumab
🥰Excellent
Purity: 95%
Catalog No. T76710Alias SHP-643, SHP643, DX-2930, DX2930Cas No. 1426055-14-2
Lanadelumab (SHP643) is a humanized IgG1 monoclonal antibody targeting plasma kallikrein (pKal) with a Ki value of 0.12 nM. Lanadelumab effectively inhibits both free pKal and its interaction with high molecular weight kininogen (HMWK)-bound pKal. Lanadelumab has demonstrated potential in hereditary angioedema research and represents a promising therapeutic antibody for studying kallikrein-kinin system regulation.
| Pack Size | Price | Availability | Quantity |
|---|---|---|---|
| 1 mg | $247 | In Stock | |
| 5 mg | $647 | In Stock | |
| 10 mg | $987 | In Stock |
Add to Cart
Add to Quotation
Bulk & Custom
All TargetMol products are for research purposes only and cannot be used for human consumption. We do not provide products or services to individuals. Please comply with the intended use and do not use TargetMol products for any other purpose.
Questions
View MoreBatch Information
Select Batch
Concentration:8.87 mg/mL
Purity:95%
Contact us for more batch information
Resource Download
Product Introduction
Bioactivity
Chemical Properties
| Description | Lanadelumab (SHP643) is a humanized IgG1 monoclonal antibody targeting plasma kallikrein (pKal) with a Ki value of 0.12 nM. Lanadelumab effectively inhibits both free pKal and its interaction with high molecular weight kininogen (HMWK)-bound pKal. Lanadelumab has demonstrated potential in hereditary angioedema research and represents a promising therapeutic antibody for studying kallikrein-kinin system regulation. |
| Targets&IC50 | pKal:0.12 nM (Ki) |
| In vitro | Lanadelumab (0-1000 nM) inhibits the proteolytic activity of pKal toward its endogenous substrate, single-chain HMWK. Furthermore, in vitro studies demonstrate that Lanadelumab potently prevents HMWK proteolysis and the subsequent release of bradykinin, with an IC50 of 1.3 nM.[2] |
| In vivo | Lanadelumab (20 mg/kg; i.v. or s.c.) exhibits an extended half-life of approximately 12.5 days and effectively blocks high molecular weight kininogen proteolysis in activated plasma in a dose- and time-dependent manner in cynomolgus monkeys. Additionally, Lanadelumab (1, 30 mg/kg; s.c.) significantly inhibits carrageenan-induced paw edema in male Sprague-Dawley rats.[2] |
| Synonyms | SHP-643, SHP643, DX-2930, DX2930 |
| Cas No. | 1426055-14-2 |
| Color | Transparent |
| Appearance | Liquid |
Storage & Solubility Information
| Storage | store at low temperature | store at -20°C | Shipping with blue ice/Shipping at ambient temperature. |
Calculator
In Vivo Formulation Calculator (Clear solution)
Please enter your animal experiment information in the following box and click Calculate to obtain the mother liquor preparation method and in vivo formula preparation method:
For example, your dosage is 10 mg/kg Each animal weighs 20 g, and the dosage volume is 100 μL . A total of 10 animals were administered, and the formula you used is 5% 
DMSO+30% PEG300+5% Tween 80+60% Saline/PBS/ddH2O. So your working solution concentration is 2 mg/mL。Mother liquor preparation method: 2 mg of drug dissolved in 50 μL DMSO (mother liquor concentration of 40 mg/mL), if you need to configure a concentration that exceeds the solubility of the product, please contact us first.
(mother liquor concentration of 40 mg/mL), if you need to configure a concentration that exceeds the solubility of the product, please contact us first.Preparation method for in vivo formula: Take 50 μL DMSO main solution, add 300 μLPEG300 mix well and clarify, then add 50 more μL Tween 80, mix well and clarify, then add 600 more μLSaline/PBS/ddH2O mix well and clarify
main solution, add 300 μLPEG300 mix well and clarify, then add 50 more μL Tween 80, mix well and clarify, then add 600 more μLSaline/PBS/ddH2O mix well and clarifyFor Reference Only. Please develop an appropriate dissolution method based on your laboratory animals and route of administration.
Dose Conversion
You can also refer to dose conversion for different animals. More Dose Conversion
Sci Citations
Tech Support
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc
Preview
Related Tags: buy Lanadelumab | purchase Lanadelumab | Lanadelumab cost | order Lanadelumab | Lanadelumab in vivo | Lanadelumab in vitro
- TOP
Feedback
Hello! How can I help you today? 
Copyright © 2015-2025 TargetMol Chemicals Inc. All Rights Reserved.